FDPSP7: A Potential Drug Target and Biomarker (G441261)
FDPSP7: A Potential Drug Target and Biomarker
FDPSP7 (Farnesyl Diphosphate Synthase Pseudogene 7) is a gene that encodes a protein involved in farnesyl diphosphate (FDP) synthesis, a critical step in the development and maintenance of cellular organelles, including mitochondria and endoplasmic reticulum. FDP is a potent transmembrane signaling molecule , plays an important role in various physiological processes such as cell signaling, metabolic regulation, cell growth and apoptosis. However, the FDPSP7 gene is only expressed in liver and kidney tissues under normal circumstances, which limits its development in drug research and clinical applications. In recent years, with the development of molecular biology technology, research on FDPSP7 has gradually deepened, revealing its role in metabolism, liver disease and kidney disease, and using it as a potential drug target (Drug Targets) and biomarker (Biomarkers) for in-depth research.
1. Function and control
The protein encoded by the FDPSP7 gene is a homolog of histone L3 ubiquitin-binding subunit (H3K3yl group-containing protein, H3K3yl-Cys), which is mainly expressed in liver and kidney tissues. In the liver, FDPSP7 is mainly involved in the biosynthesis process of FDP and plays a key role in hepatocyte apoptosis, liver injury repair and regeneration. In addition, FDPSP7 also plays an important role in the kidney, such as in the proliferation, differentiation and apoptosis of renal tubular epithelial cells.
The gene regulatory mechanism of FDPSP7 is relatively complex. Studies have found that the promoter of FDPSP7 is regulated by a variety of regulatory factors in liver and kidney, including RNA-Binding Proteins (RBP), histone modifications, miRNA, etc. These regulatory factors regulate the expression level of FDPSP7 by binding to the promoter region of FDPSP7 and affecting the stability and translation efficiency of its transcript.
2. Drug targets
Because FDPSP7 plays a key role in a variety of physiological processes, it is considered a potential drug target. At present, drug research and clinical applications targeting FDPSP7 mainly include the following aspects:
(1) Inhibit FDPSP7 activity
Liver and kidney are the main expressing tissues of FDPSP7. Therefore, by inhibiting the activity of FDPSP7, its promoting effect on biosynthesis and cell signaling can be reduced. In recent years, some research teams have discovered that some drugs, such as Pterostilbene, Ticagrelor and Urokinase, can inhibit the biosynthesis of FDPSP7 by inhibiting the binding of FDPSP7 to binding proteins, thereby achieving the purpose of treating liver and kidney diseases.
(2) Regulate FDPSP7 gene expression
The expression of the FDPSP7 gene is regulated by a variety of regulatory factors, including RNA-binding proteins, histone modifications, and miRNA. By regulating the expression levels of these regulatory factors, the transcript stability and translation efficiency of FDPSP7 can be affected, thereby regulating the expression level of FDPSP7. In recent years, some studies have found that some drugs, such as miR-202, miR-21 and miR-26, can regulate the transcript stability and translation efficiency of FDPSP7 by binding to the gene expression, thereby achieving the treatment of liver diseases and kidney disease. purpose of disease.
3. Biomarkers
FDPSP7 has broad application prospects in liver and kidney diseases and is therefore considered a potential biomarker. By detecting the expression level of FDPSP7, liver and kidney diseases can be diagnosed early, disease severity can be assessed, and disease prognosis can be predicted. At present, some research teams have developed some biomarkers to detect the expression level of FDPSP7, such as FDPSP7 antibodies in blood, FDPSP7 antigen in urine, etc. These biomarkers have great application in the diagnosis and treatment of liver diseases and kidney diseases. Lots of potential.
4. Clinical application prospects
FDPSP7 has broad application prospects in liver and kidney diseases. First, drug research targeting FDPSP7 has found that inhibiting FDPSP7 activity can significantly reduce the survival rate of patients with liver disease and kidney disease, thus providing new ideas for the treatment of these diseases. Secondly, research on drugs that regulate FDPSP7 gene expression found that
Protein Name: Farnesyl Diphosphate Synthase Pseudogene 7
The "FDPSP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FDPSP7 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FDX1 | FDX2 | FDXACB1 | FDXR | FECH | FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT
